Elranatamab in Relapsed/Refractory Multiple Myeloma

Part of paid clinical trials in La Jolla, California.

Sponsor
University of California, San Diego
Study ID
NCT06711705
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Elranatamab — DRUG
    Subcutaneous injection of elranatamab. If patient achieves MRD negative remission, patient would enter treatment-free observation period with MRD monitoring.

Study Details

This study evaluates the efficacy of elranatamab alone in patients with relapsed and/or refractory Multiple myeloma who has previously received 1 to 3 combinations of treatment.

Key Dates

Start date
Dec 18, 2024
Status verified
Feb 2026
Primary completion
Dec 31, 2029
Completion
Dec 31, 2030

Study Design

Enrollment
33 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Elranatamab
    Treatment with elranatamab

Primary Outcome Measure

MRD negativity rate as best response [ Time Frame: 1 year of starting treatment ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of California San DiegoLa JollaCalifornia92037
Ah-Reum Jeong, MD
[email protected]
(858) 822-5354
Ah-Reum Jeong, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in La Jolla, CA

By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
University of California San Diego· La Jolla, CA

Related Studies